NCT07816198Not yet recruitingPhase 3
A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy in Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 354 (estimated)
- First submitted
- 7 Sept 2026
- Start date
- 30 Sept 2026
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- Addpharma Inc.
- Diseases
- Type 2 diabetes
- NCT number
- NCT07816198
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 354
- From 30 Sept 2026 to the primary completion date, 30 Jun 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Subjects with severe diabetic complications
- Other exclusions applied
Who the study is looking for
- Signed informed consent
- Other inclusions applied
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.